Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
Aprea Therapeutics (NASDAQ: APRE) announced presentations of clinical trial data for eprenetapopt at the 63rd American Society of Hematology Annual Meeting. Key oral presentations include long-term follow-up results combining eprenetapopt with azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia, scheduled for December 11 and 12, 2021. A poster presentation is also planned for December 13, 2021, featuring a Phase I study of eprenetapopt with venetoclax and azacitidine for TP53-mutant AML. The company continues to develop innovative therapies targeting mutant p53.
Aprea Therapeutics, Inc. (Nasdaq: APRE) presented data from its Phase I/II trial at ESMO Congress 2021, evaluating the efficacy of eprenetapopt in combination with pembrolizumab for advanced solid tumors. As of July 31, 2021, 33 patients were enrolled, with no dose-limiting toxicities reported. The trial showed promising results, including complete remission in a bladder cancer patient and tumor reductions in lung cancer patients. Adverse events were primarily grade 1/2. Despite a previous trial failure for MDS, the company continues to progress with eprenetapopt in various cancers.
Aprea Therapeutics (Nasdaq: APRE) announced a presentation of data regarding eprenetapopt in combination with pembrolizumab for treating advanced solid tumors at the ESMO Congress 2021, scheduled from September 16-21, 2021. This presentation will cover the Phase I/II study and is set for September 20, 2021. The company is focused on developing therapies targeting the mutant tumor suppressor protein p53. Notably, a pivotal Phase 3 clinical trial of eprenetapopt in TP53 mutant myelodysplastic syndromes recently failed to meet its primary endpoint.
Aprea Therapeutics (Nasdaq: APRE) reported its financial results for Q2 2021, showing a net loss of $10.3 million or $0.48 per share, improved from a net loss of $16.4 million or $0.78 per share in Q2 2020. As of June 30, 2021, the company had $69.8 million in cash, projected to sustain operations into 2023. However, the FDA placed partial clinical holds on trials for eprenetapopt, affecting enrollment, despite positive results in some ongoing studies. The company emphasizes ongoing efforts to resolve these holds with the FDA and to present trial data at future conferences.
Aprea Therapeutics (Nasdaq: APRE) announced a clinical hold by the FDA on its trial evaluating eprenetapopt in combination with acalabrutinib or venetoclax and rituximab for lymphoid malignancies. This follows a previous clinical hold on its myeloid malignancies program, stemming from concerns regarding safety and efficacy data from a Phase 3 trial. Patients who are currently benefiting from the study can continue treatment, yet no new patients can be enrolled until the hold is lifted. Aprea is committed to working with the FDA to resolve these issues promptly.
Aprea Therapeutics (Nasdaq: APRE) announced a partial clinical hold on its eprenetapopt trials in myeloid malignancies after a review by the FDA. About 20 patients are currently in the program, which includes MDS and AML, and can continue treatment. No new enrollments are permitted until the hold is resolved. Aprea aims to address FDA concerns and resume trials quickly. Ongoing trials in lymphoid malignancies and solid tumors remain unaffected. A webcast to discuss the situation will be held on August 6, 2021.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced positive results from a Phase 2 trial of eprenetapopt combined with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. The trial showed a 58% relapse-free survival and 79% overall survival at one year post-transplant. Previous trials reported much lower outcomes, indicating the potential impact of this therapy. The regimen was well tolerated, and discussions with the FDA are planned. Aprea has received multiple designations for its products aimed at treating hematologic malignancies.
Aprea Therapeutics (Nasdaq: APRE) announced promising results from its Phase 1/2 trial of eprenetapopt combined with venetoclax and azacitidine for treating TP53 mutant AML. The trial met its primary efficacy endpoint, achieving a 37% complete remission rate among 30 efficacy-evaluable patients, with a composite response rate of 53%. The findings will be discussed with the FDA in the latter half of 2021, and Aprea aims to present further data at upcoming conferences. The company continues to advance its myeloid malignancies program, leveraging the potential of eprenetapopt.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced on May 21, 2021, that Greg Korbel, Senior Vice President and Chief Business Officer, will present a corporate update at the 2021 Oppenheimer Rare & Orphan Disease Summit at 3:45 p.m. ET. A webcast can be accessed on the Aprea website. The company focuses on novel cancer therapeutics, primarily targeting the p53 tumor suppressor protein. Their lead candidate, eprenetapopt (APR-246), has received multiple FDA designations for conditions including myelodysplastic syndromes and acute myeloid leukemia. A next-generation candidate, APR-548, is also in development.
Aprea Therapeutics (Nasdaq: APRE) announced participation by CEO Christian S. Schade and CMO Eyal C. Attar in a fireside discussion at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 2:30 p.m. ET. The conference will explore Aprea's focus on developing cancer therapeutics targeting mutant p53 protein. Their lead candidate, eprenetapopt (APR-246), has received multiple FDA designations for various cancers. A webcast of the event will be available on their website.